The company said, “Revenues are expected to grow approximately 14-20% compared to 2024. The company will continue to prioritize expense management, focusing its investments on the execution of multiple upcoming commercial launches and advancing multiple Phase 3 programs. Together, this is expected to lead to a reduction in 2025 net cash used in operations compared to 2024.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- RARE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ultragenyx Pharmaceuticals: Buy Rating Supported by Promising Gene Therapy Trial Results and Regulatory Advancements
- Ultragenyx Pharmaceutical’s UX111 Poised for Success: Buy Recommendation Backed by Promising Clinical Data and Strong Pipeline
- Ultragenyx announces new data on UX111 AV gene therapy
- Top 3 Trending Stocks, According to Analysts – 1/15/2025